NCT06704555View on ClinicalTrials.gov

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 30, 2027

Conditions
Follicular Lymphoma
Interventions
RADIATION

radiation therapy

received radiation (dose:18～24Gy)

DRUG

Tiselizumab

200 mg iv day 1

DRUG

Rituximab

375 mg/m2 intravenous \[IV\] day 2

DRUG

Cyclophosphamide

750 mg/m2 IV day 3

DRUG

Doxorubicin

50 mg/m2 IV day 3

DRUG

Vincristine

1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3

DRUG

Prednisone

100 mg oral days 3-7

Trial Locations (1)

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER